Cardiology Medical News about Nebivolol

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Nebivolol, a Vasodilating Selective beta-1-Blocker, Is a beta-3-Adrenoceptor Agonist in the Nonfailing Transplanted Human Heart
JACC - Journal of the American College of Cardiology, 05/04/09

Rozec B et al. - The study demonstrated that nebivolol activated beta-3-AR in the human ventricle. The NO-dependent negative inotropic effect of nebivolol associated with its vasodilating properties previously described in human microcoronary arteries could improve the energetic balance in heart. Those effects could explain the improvement of hemodynamic parameters obtained in patients with heart failure after nebivolol administration as previously described in clinical trials.

<< Previous
Postprandial hyperglycemia as an etiological factor in vascular...

Next >>
Efficacy of Ranolazine in Patients With Chronic Angina